ProPhase Labs Q1 Revenue Plunges 67% to $478K, Reports $(0.43) EPS Amid Restructuring
PRPH sits 35% above its 52-week low of $0.068 on light trading volume (0.2× avg).
Summary
ProPhase Labs reported a sharp Q1 2026 financial decline, with revenue plummeting 66.6% year-over-year to $478K and a diluted loss per share of $(0.43). This follows recent disclosures of a going concern warning, subsidiary bankruptcy, and critically low cash. The significant revenue drop and continued losses further underscore the company's severe financial distress and operational challenges, particularly after ceasing COVID diagnostic services and lower supplement sales. These results reinforce the substantial doubt about the company's ability to continue as a going concern.
At the time of this announcement, PRPH was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $873.4K. The 52-week trading range was $0.07 to $66.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.